Back to mobile site
Get it on Google Play

Prime Medicine doses first patient in Wilson disease gene editing trial

October 5, 2026 8:00 AM EDT Send to a Friend
Prime Medicine, Inc. (Nasdaq: PRME) announced that the first patient has been dosed in its global Phase 1/2 clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login